Biomea Fusion (BMEA) Other Non-Current Assets (2020 - 2026)
Biomea Fusion (BMEA) posted Other Non-Current Assets of $369000.0 for Q4 2025, up 9125.0% sequentially from $4000.0 in Q2 2025, and little changed YoY from $369000.0 in Q4 2024.
Biomea Fusion (BMEA) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Biomea Fusion has reported Other Non-Current Assets for 6 years, with the latest figure at $369000.0 in Q4 2025.
- Quarterly Other Non-Current Assets changed 0.0% year-over-year to $369000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $369000.0 (changed 0.0% YoY) and the FY2025 annual result came in at $369000.0, changed 0.0% from the prior year.
- Other Non-Current Assets grew to $369000.0 in Q4 2025 per BMEA's latest filing, from $4000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $370000.0 in Q4 2023 and troughed at $4000.0 in Q2 2025.
- A 5-year average of $319052.6 and a median of $351000.0 in 2021 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2021 and 2025: Other Non-Current Assets soared 2825.0% in 2021, then plunged 98.92% in 2025.
- Over 5 years, Other Non-Current Assets stood at $351000.0 in 2021, then changed by 0.0% to $351000.0 in 2022, then rose by 5.41% to $370000.0 in 2023, then declined by 0.27% to $369000.0 in 2024, then changed by 0.0% to $369000.0 in 2025.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $369000.0, $4000.0, and $369000.0 for Q4 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Biomea Fusion | 97.69 Mn | 97.69 Mn | - | 398,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 398,000.00 |
| Mar 31, 2026 | 369,000.00 |
| Dec 31, 2025 | 369,000.00 |
| Jun 30, 2025 | 4,000.00 |
| Mar 31, 2025 | 369,000.00 |
| Dec 31, 2024 | 369,000.00 |
| Sep 30, 2024 | 369,000.00 |
| Jun 30, 2024 | 369,000.00 |
| Mar 31, 2024 | 369,000.00 |
| Dec 31, 2023 | 370,000.00 |
| Sep 30, 2023 | 369,000.00 |
| Jun 30, 2023 | 351,000.00 |
| Mar 31, 2023 | 351,000.00 |
| Dec 31, 2022 | 351,000.00 |
| Sep 30, 2022 | 351,000.00 |
| Jun 30, 2022 | 351,000.00 |
| Mar 31, 2022 | 351,000.00 |
| Dec 31, 2021 | 351,000.00 |
| Sep 30, 2021 | 216,000.00 |
| Jun 30, 2021 | 216,000.00 |